Advanced search
Start date

Evaluation of the anti-neoplastic activity of tributyrin alone or in combination with sorafenib in Fischer 344 and Nude rowett rats


Hepatocellular carcinoma (HCC) is the fifth most frequent type of cancer in the world, and is the third leading cause of mortality due to its low rate of remission. Therefore, it is important to develop chemopreventive strategies in order to reduce reappearance of HCC together with treatment of the primary neoplasia. Tributyrin (TB) showed chemopreventive activity when administered during the initiation and promotion, or only promotion, phases of experimental chemical carcinogenesis. TB caused a reduction in incidence and size of preneoplastic lesions, as well as induction of apoptosis and hyperacetylation of histones. Sorafenib is an efficacious chemotherapeutic agent used for treatment of many different cancers, including HCC. However, there are reports of patients resistant to sorafenib treatment. Thus, this study aims to evaluate the potential anti-neoplastic action of TB (or placebo) in association with sorafenib during the progression phase of hepatocarcinogenesis. The expectation is that TB will potentiate the effects of sorafenib. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
MORENO, FERNANDO SALVADOR; HEIDOR, RENATO; POGRIBNY, IGOR P.. Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, v. 68, n. 5, p. 719-733, . (13/20477-6)

Please report errors in scientific publications list by writing to: